Firas B Badin, MD
Clinical Focus
Practice Locations
Lexington, KY 40503
Lexington, KY 40509
Education
Newark Beth Israel Med Ctr
Medical SchoolUniversity of Damascus School of Medicine
FellowshipUniversity of Kentucky Medical Center
ResidencyNewark Beth Israel Med Ctr
Board Certifications
American Board of Internal Medicine
HematologyAmerican Board of Internal Medicine
Hospital Affiliations
- Baptist Health Richmond
- Baptist Health Lexington
Philosophy of Care
Research
-
Advanced Non-Small Cell Lung Cancer; Metastatic Cancer
Krystal 007: A Phase 2 Trial of MRTX849 in Combination with Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation
Trial Details -
Extensive-stage Small-cell Lung Cancer
EMERGE 402: Stage IV observational study for adult patients with metastatic SCLC
Trial Details -
Lung Cancer
A081801-Alchemist Sub-Study: This phase III ALCHEMIST trial compares the addition of pembrolizumab to usual chemotherapy versus usual chemotherapy for the treatment of stage IB, II, or IIIA non-small cell lung cancer that has been removed by surgery.
Trial Details -
Lung Cancer
Alliance A151216: ALCHEMIST - Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial
Trial Details -
Lung Cancer
ECOG-ACRIN E4512: A Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer
Trial Details -
Non Small Cell Lung Cancer
QUILT -2.023:A phase 2, open-label, randomized study of ALT-803 in combination with pembrolizumab vs pembrolizumab alone as first-line treatment for patients with metastatic NSCLC
Trial Details -
Non Small Cell Lung Cancer
Phase 2, Open-Label, Multicenter, Randomized, Multi-Drug Platform Study of Durvalumab Alone or in Combination with Novel Agents in Subject with Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (COAST)
Trial Details -
Non Small Cell Lung Cancer
BeiGene A317-A1217- 301: Phase 3, Randomized, Open-Label Study to Compare Tislelizumab (BGB-A317) Plus Anti-TIGIT Monoclonal Antibody BGB-A1217 Plus Concurrent Chemoradiotherapy (cCRT) Followed by Tislelizumab Plus BGB-A1217
Trial Details -
Non Small Cell Lung Cancer; Triple Negative Breast Cancer; Melanoma; Head and Neck Cancer
BA3021-001: Phase 1/2 dose escalation and dose expansion study of BA3021 alone and in combination with Nivo in patients with advanced solid tumors
Trial Details -
Non-small Cell Lung Cancer
EF-36/Keynote: A pilot, single arm, open-label study of Tumor Treating Fields (TTFields, 150 kHz) concomitant with pembrolizumab for first line treatment of advanced or metastatic intrathoracic non-small cell lung cancer
Trial Details -
Non-small Cell Lung Cancer (NSCLC)
Pacific 9: A Phase III, double-blind, placebo-controlled, Randomized, Multicentre, International Study of Durvalumab Plus Oleclumab and Durvalumab Plus Monalizumab in Patients With Locally Advanced (Stage III), Unresectable Non-small Cell Lung Cancer (NSCLC) Who Have Not Progressed Following Definitive, Platinum-Based Concurrent Chemoradiation Therapy
Trial Details -
Non-small Cell Lung Cancer (NSCLC)
BeiGene A317-A1217-302: A Phase 3, Randomized, Double-Blind Study of BGB-A1217, an Anti-TIGIT Antibody, in Combination With Tislelizumab Compared to Pembrolizumab in Patients With Previously Untreated, or Metastatic Non-Small Cell Lung Cancer
Trial Details -
Non-small Cell Lung Cancer (NSCLC) (WIRB-22-0106)
Skyscraper: A Phase II/III, Randomized, Double Blind, Placebo-Controlled Study of Tiragolumab in Combination with Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin Versus Pembrolizumab
Trial Details -
Non-small Cell Lung Cancer<br> Recurrent Non-small Cell Lung Cancer <br>Metastatic Non-small Cell Lung Cancer
CA224-104: A Phase 2 Randomized Double-blind Study of Relatlimab plus Nivolumab in Combination with Chemotherapy vs. Nivolumab in Combination with Chemotherapy as First Line Treatment for Participants with Stage IV or Recurrent Non-small Cell Lung Cancer
Trial Details -
Non-Small-Cell Lung Cancer
BA3011-002: A Phase 2 study of BA3011 alone and in combination with Nivolumab in adult patients with metastatic non-small cell lung cancer (NSCLC) who had prior disease progression on a PD-1/L-1 Inhibitor
Trial Details -
NSC Lung Cancer
Razor-Encore - A Randomized Prospective Trial of Adjuvant Chemotherapy in Patients With Completely Resected Stage I or IIA Non-Squamous Non-Small Cell Lung Cancer Identified as Intermediate or High Risk by a 14-Gene Prognostic Assay
Trial Details -
Previously Treated Non-Small Cell Lung Cancer
LungMAP: A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study)
Trial Details -
Small Cell Lung Cancer
MK3475-B99: A Phase 2 Study to Evaluate Efficacy and Safety of Pembrolizumab plus Investigational Agents in Combination with Etoposide and Cisplatin or Carboplatin for First-Line Treatment of Extensive-Stage Small Cell Lung Cancer (Keynote-B99)
Trial Details -
Small Cell Lung Carcinoma
MK3475-B98: A Phase 1b/2 Study to Evaluate Efficacy and Safety of Pembrolizumab in Combination w Investigational Agents for Treatment of Participants With PD-1/L1- refractory Extensive-Stage Small Cell Lung Cancer in Need of Second-Line Therapy (Keynote-B
Trial Details